All News

15 January 2008

ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLEAntibodies

15 January 2008

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus ErythematosusAntibodies

15 January 2008

Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody TherapyAntibodies

15 January 2008

BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204, a potential treatment for cardiovascular conditions associated with atherosclerosisAntibodies

14 January 2008

FDA Approves TYSABRI(R) For The Treatment Of Moderate-To-Severe Crohn’s DiseaseAntibodies

9 January 2008

TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric AntibodyAntibodies

8 January 2008

Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune DiseasesAntibodies

8 January 2008

Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411Antibodies

8 January 2008

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to OphthotechAntibodies

7 January 2008

Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin LymphomaAntibodies

4 January 2008

Genmab Announces HuMax-CD32B Pre-Clinical ProgramAntibodies

3 January 2008

Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against RabiesAntibodies

3 January 2008

ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer CompoundsAntibodies

3 January 2008

Expanded Labeling for MabCampath(R) in EuropeAntibodies

30 December 2007

MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 ProgramAntibodies

22 December 2007

Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer’s DiseaseAntibodies

21 December 2007

Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab (R) for the treatment of malignant ascitesAntibodies

21 December 2007

Centocor, Schering-Plough Revise Agreement Covering REMICADE, GolimumabAntibodies

20 December 2007

Ablinx Extends Agreement With WyethAntibodies

20 December 2007

Abbott’s HUMIRA (R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque PsoriasisAntibodies

20 December 2007

R1507 antibody to enter Phase II study to treat sarcomaAntibodies

20 December 2007

Human Genome Sciences initiates second randomized Phase 2 trial of HGS- ETR 1 in combination with chemotherapyAntibodies

19 December 2007

Avastin approved in Europe for first-line treatment of patients with advanced kidney cancerAntibodies

17 December 2007

Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081Antibodies

17 December 2007

Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren’s ContractureAntibodies

14 December 2007

Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor TherapyAntibodies

13 December 2007

WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX(R)Antibodies

13 December 2007

Genmab initiates Ofatumumab Phase II study in diffuse large b-cell lymphomaAntibodies

13 December 2007

Genmab announces details of planned Ofatumumab Phase II study in multiple sclerosisAntibodies

13 December 2007

Merck Announces Initiation of Phase II/III Clinical Trial of Atacicept in Lupus NephritisAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

TROP-2-Targeted Immunotherapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

CD40 Agonists & CD40/L Antagonists Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

TL1A Inhibitor Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review